Cell Reports MedicinePub Date : 2024-10-15Epub Date: 2024-10-04DOI: 10.1016/j.xcrm.2024.101764
Xiaoqing Yu, Li Song, Ling Cen, Biwei Cao, Ranran Tao, Yuanyuan Shen, Daniel Abate-Daga, Paulo C Rodriguez, Jose R Conejo-Garcia, Xuefeng Wang
{"title":"Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential.","authors":"Xiaoqing Yu, Li Song, Ling Cen, Biwei Cao, Ranran Tao, Yuanyuan Shen, Daniel Abate-Daga, Paulo C Rodriguez, Jose R Conejo-Garcia, Xuefeng Wang","doi":"10.1016/j.xcrm.2024.101764","DOIUrl":"10.1016/j.xcrm.2024.101764","url":null,"abstract":"<p><p>Gamma-delta T cells (γδ T cells) play a crucial role in both innate and adaptive immunity within tumors, yet their presence and prognostic value in cancer remain underexplored. This study presents a large-scale analysis of γδ T cell receptor (γδ TCR) reads from 11,000 tumor samples spanning 33 cancer types, utilizing the TRUST4 algorithm. Our findings reveal extensive diversity in γδ TCR clonality and gene expression, underscoring the potential of γδ T cells as prognostic biomarkers in various cancers. We further demonstrate the utility of TCR gamma (TRG) and delta (TRD) gene expression from standard RNA-sequencing (RNA-seq) data. This comprehensive dataset offers a valuable resource for advancing γδ T cell research, with implications for enhanced immunotherapy approaches or alternative therapeutic strategies. Additionally, our centralized database supports translational research into the therapeutic significance of γδ T cells.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-10-15Epub Date: 2024-10-08DOI: 10.1016/j.xcrm.2024.101784
Li-Bo Zhang, Yu-Xin Chen, Zhen-Jiang Li, Xin-Yi Geng, Xiang-Yue Zhao, Feng-Rui Zhang, Yan-Zhi Bi, Xue-Jing Lu, Li Hu
{"title":"Advances and challenges in neuroimaging-based pain biomarkers.","authors":"Li-Bo Zhang, Yu-Xin Chen, Zhen-Jiang Li, Xin-Yi Geng, Xiang-Yue Zhao, Feng-Rui Zhang, Yan-Zhi Bi, Xue-Jing Lu, Li Hu","doi":"10.1016/j.xcrm.2024.101784","DOIUrl":"10.1016/j.xcrm.2024.101784","url":null,"abstract":"<p><p>Identifying neural biomarkers of pain has long been a central theme in pain neuroscience. Here, we review the state-of-the-art candidates for neural biomarkers of acute and chronic pain. We classify these potential neural biomarkers into five categories based on the nature of their target variables, including neural biomarkers of (1) within-individual perception, (2) between-individual sensitivity, and (3) discriminability for acute pain, as well as (4) assessment and (5) prospective neural biomarkers for chronic pain. For each category, we provide a synthesized review of candidate biomarkers developed using neuroimaging techniques including functional magnetic resonance imaging (fMRI), structural magnetic resonance imaging (sMRI), and electroencephalography (EEG). We also discuss the conceptual and practical challenges in developing neural biomarkers of pain. Addressing these challenges, optimal biomarkers of pain can be developed to deepen our understanding of how the brain represents pain and ultimately help alleviate patients' suffering and improve their well-being.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cell Reports MedicinePub Date : 2024-10-15Epub Date: 2024-10-08DOI: 10.1016/j.xcrm.2024.101786
Jing Wang, Lisa V Doan
{"title":"Clinical pain management: Current practice and recent innovations in research.","authors":"Jing Wang, Lisa V Doan","doi":"10.1016/j.xcrm.2024.101786","DOIUrl":"10.1016/j.xcrm.2024.101786","url":null,"abstract":"<p><p>Chronic pain affects one in five adults. It is not only a major cause of disability for individual patients but also a driver of costs for entire healthcare systems. Treatment of pain remains a challenge, and the use of opioids has further led to a concurrent opioid epidemic. In this review, we discuss current standard treatment options for chronic pain, including pharmacological, behavioral, and interventional treatments. In addition, we review ongoing research in different areas that will potentially unlock new therapies.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiangyun Yao, Lingchi Kong, Yi Qiao, David Brand, Juehong Li, Zhiwen Yan, Song Guo Zheng, Yun Qian, Cunyi Fan
{"title":"Schwann cell-secreted frizzled-related protein 1 dictates neuroinflammation and peripheral nerve degeneration after neurotrauma.","authors":"Xiangyun Yao, Lingchi Kong, Yi Qiao, David Brand, Juehong Li, Zhiwen Yan, Song Guo Zheng, Yun Qian, Cunyi Fan","doi":"10.1016/j.xcrm.2024.101791","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101791","url":null,"abstract":"<p><p>Neurotrauma in limbs can induce sustained neuroinflammation, resulting in persistent disruption of nerve tissue architecture and retardation of axon regrowth. Despite macrophage-mediated inflammation promoting the removal of necrotic neural components and stimulating neo-vessel ingrowth, detrimental shifts in macrophage phenotype exacerbate nerve degeneration. Herein, we find that peripheral nerve injuries (PNIs) result in abundant secreted frizzled-related protein 1 (sFRP1) expression, particularly by Schwann cells (SCs). Heat shock protein 90 (HSP90) in macrophages recognizes sFRP1 and triggers a dysregulated secretion of inflammatory mediators. Single-cell atlas of human injured peripheral nerves reveals the appearance of sFRP1-expressing SCs with mesenchymal traits and macrophages with a proinflammatory genetic profile. Deletion of either SC-specific sFRP1 or macrophage-specific HSP90 alleviates neuroinflammation and prevents the progression of nerve degeneration. Together, our findings implicate the response of macrophages to SC-derived sFRP1 in exacerbating nerve damage following PNIs.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Avantika Gupta, Flavia Michelini, Hong Shao, Celine Yeh, Joshua Z Drago, Dazhi Liu, Eric Rosiek, Yevgeniy Romin, Negin Ghafourian, Sheeno Thyparambil, Sandra Misale, Wungki Park, Elisa de Stanchina, Yelena Y Janjigian, Rona Yaeger, Bob T Li, Sarat Chandarlapaty
{"title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy.","authors":"Avantika Gupta, Flavia Michelini, Hong Shao, Celine Yeh, Joshua Z Drago, Dazhi Liu, Eric Rosiek, Yevgeniy Romin, Negin Ghafourian, Sheeno Thyparambil, Sandra Misale, Wungki Park, Elisa de Stanchina, Yelena Y Janjigian, Rona Yaeger, Bob T Li, Sarat Chandarlapaty","doi":"10.1016/j.xcrm.2024.101792","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101792","url":null,"abstract":"<p><p>Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody drug conjugate that has remarkable activity in HER2-positive cancers. However, the degree of benefit of T-DXd is not uniform among solid tumors even with high levels of HER2. Despite high HER2 expression, the HER2/T-DXd complex may not always undergo internalization and payload release dependent on the receptor's conformation and context. We hypothesize that epidermal growth factor receptor (EGFR), a dimerization partner of HER2, can modulate HER2 trafficking through endocytic pathways and affect T-DXd uptake. We demonstrate that elevated EGFR expression levels can promote EGFR/HER2 heterodimer formation and suppress T-DXd internalization and efficacy. Knockdown of EGFR expression or pharmacologic stimulation of EGFR endocytosis with EGFR monoclonal antibodies restores T-DXd trafficking and antitumor activity in EGFR-overexpressing cancers in vivo. Our results reveal EGFR overexpression to be a potential mechanism of resistance to T-DXd, which can be overcome by combination therapy strategies targeting EGFR.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amélie M Borie, Yann Dromard, Prabahan Chakraborty, Pierre Fontanaud, Emilie M Andre, Amaury François, Pascal Colson, Françoise Muscatelli, Gilles Guillon, Michel G Desarménien, Freddy Jeanneteau
{"title":"Neuropeptide therapeutics to repress lateral septum neurons that disable sociability in an autism mouse model.","authors":"Amélie M Borie, Yann Dromard, Prabahan Chakraborty, Pierre Fontanaud, Emilie M Andre, Amaury François, Pascal Colson, Françoise Muscatelli, Gilles Guillon, Michel G Desarménien, Freddy Jeanneteau","doi":"10.1016/j.xcrm.2024.101781","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101781","url":null,"abstract":"<p><p>Confronting oxytocin and vasopressin deficits in autism spectrum disorders and rare syndromes brought promises and disappointments for the treatment of social disabilities. We searched downstream of oxytocin and vasopressin for targets alleviating social deficits in a mouse model of Prader-Willi syndrome and Schaaf-Yang syndrome, both associated with high prevalence of autism. We found a population of neurons in the lateral septum-activated on termination of social contacts-which oxytocin and vasopressin inhibit as per degree of peer affiliation. These are somatostatin neurons expressing oxytocin receptors coupled to GABA-B signaling, which are inhibited via GABA-A channels by vasopressin-excited GABA neurons. Loss of oxytocin or vasopressin signaling recapitulated the disease phenotype. By contrast, deactivation of somatostatin neurons or receptor signaling alleviated social deficits of disease models by increasing the duration of contacts with mates and strangers. These findings provide new insights into the treatment framework of social disabilities in neuropsychiatric disorders.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yu-Hui Lin, Feng Wu, Ting-You Li, Long Lin, Fan Gao, Li-Juan Zhu, Xiu-Mei Xu, Ming-Yu Chen, Ya-Lan Hou, Chang-Jing Zhang, Hai-Yin Wu, Lei Chang, Chun-Xia Luo, Ya-Juan Qin, Dong-Ya Zhu
{"title":"Disrupting stroke-induced GAT-1-syntaxin1A interaction promotes functional recovery after stroke.","authors":"Yu-Hui Lin, Feng Wu, Ting-You Li, Long Lin, Fan Gao, Li-Juan Zhu, Xiu-Mei Xu, Ming-Yu Chen, Ya-Lan Hou, Chang-Jing Zhang, Hai-Yin Wu, Lei Chang, Chun-Xia Luo, Ya-Juan Qin, Dong-Ya Zhu","doi":"10.1016/j.xcrm.2024.101789","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101789","url":null,"abstract":"<p><p>Although stroke is a frequent cause of permanent disability, our ability to promote stroke recovery is limited. Here, we design a small-molecule stroke recovery promoting agent that works by dissociating γ-aminobutyric acid (GABA) transporter 1 (GAT-1) from syntaxin1A (Synt1A), a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein. Stroke induces an increase in GAT-1-Synt1A interaction in the subacute phase, a critical period for functional recovery. Uncoupling GAT-1-Synt1A reverses stroke-induced GAT-1 dysfunction and cortical excitability decline and enhances synaptic GABAergic inhibition and consequently cortical oscillations and network plasticity by facilitating the assembly of the SNARE complex at the synapse. Based on the molecular mechanism of GAT-1 binding to Synt1A, we design GAT-1-Synt1A blockers. Among them, ZLQ-3 exhibits the greatest potency. Intranasal use of ZLQ-3-1, a glycosylation product of ZLQ-3, substantially lessens impairments of sensorimotor and cognitive functions in rodent models. This compound, or its analogs, may serve as a promoting agent for stroke recovery.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
William A Banks, Elizabeth M Rhea, May J Reed, Michelle A Erickson
{"title":"The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications.","authors":"William A Banks, Elizabeth M Rhea, May J Reed, Michelle A Erickson","doi":"10.1016/j.xcrm.2024.101760","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101760","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) plays central roles in the maintenance and health of the brain. Its mechanisms to safeguard the brain against xenobiotics and endogenous toxins also make the BBB the primary obstacle to the development of drugs for the central nervous system (CNS). Here, we review classic examples of the intersection of clinical medicine, drug delivery, and the BBB. We highlight the role of lipid solubility (heroin), saturable brain-to-blood (efflux: opiates) and blood-to-brain (influx: nutrients, vitamins, and minerals) transport systems, and adsorptive transcytosis (viruses and incretin receptor agonists). We examine how the disruption of the BBB that occurs in certain diseases (tumors) can also be modulated (osmotic agents and microbubbles) and used to deliver treatments, and the role of extracellular pathways in gaining access to the CNS (albumin and antibodies). In summary, this review provides a historical perspective of the key role of the BBB in delivery of drugs to the brain in health and disease.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":11.7,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma","authors":"Lihong He, Xiaozhen Zhang, Fukang Shi, Hanjia Zhang, Yan Chen, Kang Sun, Hanshen Yang, Jiatao Shi, Zihao Lin, Qingsong Lu, Sicheng Wang, Linyue Liu, Xinyuan Liu, Qingbo Meng, Junmin Huang, Pinglong Xu, Xueli Bai, Tingbo Liang","doi":"10.1016/j.xcrm.2024.101731","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101731","url":null,"abstract":"<p>Current therapies against pancreatic ductal adenocarcinoma (PDAC) have limited clinical benefits owing to tumor heterogeneity and their unique immunosuppressive microenvironments. The eukaryotic initiation factor (eIF) 4F complex is involved in regulating translation and various downstream carcinogenic signaling pathways. We report that eIF4G1, one of the subunits of eIF4F, is overexpressed in cancer cells and cancer-associated fibroblasts, and this correlates with poor prognosis in patients with PDAC. In PDAC mice, eIF4G1 inhibition limits tumor progression and prolongs overall survival, especially when combined with PD1/PDL1 antagonists and gemcitabine. Mechanistically, eIF4G1 inhibition hinders the production of cytokines and chemokines that promote fibrosis and inhibit cytotoxic T cell chemotaxis. Moreover, eIF4G1 inhibition impairs integrinβ1 protein translation and exerts tumor suppression effects through the FAK-ERK/AKT signaling pathway. These findings highlight the effects of eIF4G1 on tumor immune dependence and independence and identify eIF4G1 as a promising therapeutic target for PDAC.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ann Tivey, Rebecca J. Lee, Alexandra Clipson, Steven M. Hill, Paul Lorigan, Dominic G. Rothwell, Caroline Dive, Florent Mouliere
{"title":"Mining nucleic acid “omics” to boost liquid biopsy in cancer","authors":"Ann Tivey, Rebecca J. Lee, Alexandra Clipson, Steven M. Hill, Paul Lorigan, Dominic G. Rothwell, Caroline Dive, Florent Mouliere","doi":"10.1016/j.xcrm.2024.101736","DOIUrl":"https://doi.org/10.1016/j.xcrm.2024.101736","url":null,"abstract":"<p>Treatments for cancer patients are becoming increasingly complex, and there is a growing desire from clinicians and patients for biomarkers that can account for this complexity to support informed decisions about clinical care. To achieve precision medicine, the new generation of biomarkers must reflect the spatial and temporal heterogeneity of cancer biology both between patients and within an individual patient. Mining the different layers of 'omics in a multi-modal way from a minimally invasive, easily repeatable, liquid biopsy has increasing potential in a range of clinical applications, and for improving our understanding of treatment response and resistance. Here, we detail the recent developments and methods allowing exploration of genomic, epigenomic, transcriptomic, and fragmentomic layers of 'omics from liquid biopsy, and their integration in a range of applications. We also consider the specific challenges that are posed by the clinical implementation of multi-omic liquid biopsies.</p>","PeriodicalId":9822,"journal":{"name":"Cell Reports Medicine","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}